Providing leading edge diagnostic solutions in oncology

AccuGenomics provides gene expression tests that accurately diagnose, monitor and inform cancer treatment. AccuGenomics' technologies generate the most comprehensive test results which ensure confidence in clinical decisions and provide credible and reliable gene expression data to the medical community.

Breaking News:

Partnering with Nuclea Biotechnologies on BCRABL development

Wilmington, NC. January 1 2014. AccuGenomics, Inc. has licensed   its standardized BCRABL test to Nuclea Biotechnologies, Inc., for the treatment of Chronic Myeloid Leukemia. Nuclea will offer the BCRABL test in its CLIA laboratories and manufacture the BCRABL kits for the Northeast market. The agreement with Nuclea Biotechnologies will soon lead to more effective treatments…

Preliminary SNAQ BCR-ABL Pilot results presented at the 16th Annual John Goldman Conference on Chronic Myeloid Leukemia

Wilmington, NC. September 6 2014. AccuGenomics presented preliminary results of the SNAQ BCR-ABL pilot study conducted with MD Anderson at the 16th Annual John Goldman Conference on Chronic Myeloid Leukemia. The molecular tests for measuring of Philadelphia chromosome blood abundance has proven to be an invaluable tool for monitoring CML treatment. However, despite intense international…

AccuGenomics awarded United States patent for a molecular test that predicts lung cancer risk

WILMINGTON, July 22, 2014 – AccuGenomics Inc., a molecular tools company focused on producing methods and quality controls required to standardize molecular testing has been issued a patent for a transcript abundance method used to predict risk of bronchial carcinoma in 20 pack year smokers. The patent has issued as US 8,765,368 & US 8,771,947…

Accugenomics has received exclusive licences on STARSEQ technology from University of Toledo.

Wilmington , NC. April 7 2014. Accugenomics and The Uuniversity of Toledo have finalized a exclusive license agreement that provides Accugenomics worldwide rights to commercialize STARSEQ™ Technology. STARSEQ technology will fulfill a next generation sequencing need to run at very low cost, quality controlled and reproducible multigene transcript abundance analysis in large numbers of samples…